- In April the Company announced that the company has decided to focus fully on its most promising drug candidate, pudafensine, which is being developed for both vulvodynia and organic erectile dysfunction (ED). As part of this prioritization, the Company has discontinued further development of IP2018.
- In April the Company announced good progress in patient enrol-ment in its Phase IIa clinical proof-of-concept study evaluating pudafensine in women suffering from the genital pain condition, vulvodynia.
- In May the Company announced the resolutions of the annual general meeting, at which Christina Lloyd was elected as a new member of the board of directors. Göran Ando had declared that he was not available for re-election.
Business highlights after this reporting period
- In July the European patent covering pudafensine for the treatment of Female Sexual Dysfunction, including vulvodynia, was also granted in Hong Kong.
- On 19 August the European Patent Office granted two patents relating to pudafensine, EP 4608400 covering pudafensine for the treatment of pain including vulvodynia, and EP 4731189 covering an immediate-release oral formulation of pudafensine.
Financial Highlights
| Second Quarter (2026-04-01 – 2026-06-30) |
| Net revenue were KDKK 0 (0) |
| Operating loss, EBIT was KDKK -9,499 (-3,844) |
| Earnings per share before and after dilution was DKK -0.14 (-0.07) |
| Cash: KDKK 17,070 (26,245) |
| Solidity: 41% (88%) |
| First Six Months (2026-01-01 – 2026-06-30) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -20,931 (-6,497) |
| Earnings per share before and after dilution was DKK –0.31 (-0.12) |
Solidity: equity divided by assets.
The Board of Directors have decided that interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/